2상모집 중단 (진행 중)
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
연구 개요
The purpose of this study is to assess long-term safety and provide continued study treatment access to eligible participants who are judged by the Investigator to benefit from continued treatment with capmatinib monotherapy or in combination with other treatments or with the combination treatment alone in a Novartis sponsored study
- 스폰서
- 리드: 노바티스
- 적응증
- Advanced Solid Tumors Which Are cMET-dependent
- 중재
- Capmatinib, Nazartinib, Gefitinib, Osimertinib
- 목표 등록
- 29명
- 시작일
- 2017-08-23
- 완료(예정)
- 2027-07-30
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.